Download PDF
Thromb Haemost 2020; 120(02): 322-328
DOI: 10.1055/s-0039-3400303
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia

Fatimah Al-Ani
1   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
,
Yimin Pearl Wang
1   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
,
Alejandro Lazo-Langner 
1   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
2   Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
› Author Affiliations Funding This study was funded by the Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network which receives grant funding from the Canadian Institutes for Health Research (Grant/Award number “CDT 142654”). F.A.-A was supported by a fellowship from the CanVECTOR Network. A.L.-L. is an investigator of the CanVECTOR Network.
Further Information

Publication History

21 May 2019

26 September 2019

Publication Date:
01 January 2020 (online)

    Permissions and Reprints

Abstract

Risk factors for venous thromboembolism in patients with solid tumors are well studied; however, studies in patients with acute leukemia are lacking. We conducted a retrospective cohort study of adult patients diagnosed with acute myeloid leukemia and acute lymphoblastic leukemia diagnosed between June 2006 and June 2017 at a tertiary care center in Canada. Potential predictors of venous thromboembolism were evaluated using logistic regression and a risk score was derived based on weighed variables and compared using survival analysis. Internal validation was conducted using nonparametric bootstrapping. A total of 501 leukemia patients (427 myeloid and 74 lymphoblastic) were included. Venous thromboembolism occurred in 77(15.3%) patients with 71 events occurring in the first year. A prediction score was derived and validated and it included: previous history of venous thromboembolism (3 points), lymphoblastic leukemia (2 points), and platelet count > 50 × 109/L at the time of diagnosis (1 point). The overall cumulative incidence of venous thromboembolism was 44% in the high-risk group (≥ 3 points) versus 10.5% in the low-risk group (0–2 points) and it was consistent at different follow-up periods (log-rank p < 0.001). We derived and internally validated a predictive score of venous thromboembolism risk in acute leukemia patients.

Keywords

acute leukemia - venous thromboembolism - prediction - score
 

  • References

  • 1 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (04) 458-464
    CrossrefPubMedGoogle Scholar
  • 2 Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol 2012; 24 (06) 702-710
    CrossrefPubMedGoogle Scholar
  • 3 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 4 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 5 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 6 Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113 (17) 3911-3917
    CrossrefPubMedGoogle Scholar
  • 7 Ziegler S, Sperr WR, Knöbl P. , et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115 (1-2): 59-64
    CrossrefPubMedGoogle Scholar
  • 8 Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano MR, Cascavilla N. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117 (04) 215-220
    CrossrefPubMedGoogle Scholar
  • 9 Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 2006; 94 (02) 200-202
    CrossrefPubMedGoogle Scholar
  • 10 Vu K, Luong NV, Hubbard J. , et al. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med 2015; 4 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 11 Refaei M, Fernandes B, Brandwein J, Goodyear MD, Pokhrel A, Wu C. Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters. Ann Hematol 2016; 95 (12) 2057-2064
    CrossrefPubMedGoogle Scholar
  • 12 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
    CrossrefPubMedGoogle Scholar
  • 13 Palumbo A, Rajkumar SV, Dimopoulos MA. , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (02) 414-423
    CrossrefPubMedGoogle Scholar
  • 14 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12) 2822-2829
    CrossrefPubMedGoogle Scholar
  • 15 Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313 (13) 793-799
    CrossrefPubMedGoogle Scholar
  • 16 Henderson AR. The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta 2005; 359 (1-2): 1-26
    CrossrefPubMedGoogle Scholar
  • 17 Steyerberg EW, Harrell Jr FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54 (08) 774-781
    CrossrefPubMedGoogle Scholar
  • 18 Carrier M, Abou-Nassar K, Mallick R. , et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2018
    PubMedGoogle Scholar
  • 19 Mirza S, Yun S, Al Ali N. , et al. Validation of the Khorana score in acute myeloid leukemia patients: a single institution experience. Blood 2018; 132 (Suppl. 01) 2278-2278
    CrossrefPubMedGoogle Scholar
  • 20 Agnelli G, Bolis G, Capussotti L. , et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (01) 89-95
    CrossrefPubMedGoogle Scholar
  • 21 Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl. 02) S1-S7
    PubMedGoogle Scholar
  • 22 Louzada ML, Carrier M, Lazo-Langner A. , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
    CrossrefPubMedGoogle Scholar
  • 23 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (05) 1311-1315
    CrossrefPubMedGoogle Scholar
  • 24 Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007; 5 (03) 621-623
    CrossrefPubMedGoogle Scholar
  • 25 Sibai H, Seki JT, Wang TQ. , et al. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia. Curr Oncol 2016; 23 (04) e355-e361
    CrossrefPubMedGoogle Scholar
  • 26 Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004; 77 (04) 331-335
    CrossrefPubMedGoogle Scholar
  • 27 De Stefano V, Sorà F, Rossi E. , et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3 (09) 1985-1992
    CrossrefPubMedGoogle Scholar
  • 28 Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 2013; 27 (03) 553-559
    CrossrefPubMedGoogle Scholar
  • 29 Hunault-Berger M, Chevallier P, Delain M. , et al; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang). Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008; 93 (10) 1488-1494
    CrossrefPubMedGoogle Scholar
  • 30 Sylman JL, Mitrugno A, Tormoen GW, Wagner TH, Mallick P, McCarty OJT. Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Converg Sci Phys Oncol 2017; 3 (02) 023001
    CrossrefPubMedGoogle Scholar
  • 31 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91 (09) 3093-3102
    CrossrefPubMedGoogle Scholar
  • 32 Dombret H, Scrobohaci ML, Daniel MT. , et al. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995; 9 (01) 19-24
    PubMedGoogle Scholar
  • 33 Tallman MS, Lefèbvre P, Baine RM. , et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2 (08) 1341-1350
    CrossrefPubMedGoogle Scholar
  • 34 Libourel EJ, Klerk CPW, van Norden Y. , et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood 2016; 128 (14) 1854-1861
    PubMedGoogle Scholar
  • 35 Lee YG, Kim I, Kwon JH. , et al. Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia. Thromb Haemost 2015; 113 (01) 201-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2 (12) 2156-2161
    CrossrefPubMedGoogle Scholar